SELLAS Life Sciences (SLS) announced that the Independent Data Monitoring Committee, IDMC, has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, and has issued a positive recommendation to continue the trial without modification. The IDMC concluded that the risk-benefit profile of GPS supports continued evaluation under the current study protocol. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct. The study completed enrollment in April 2024, with a total of 126 patients randomized. Study sites in the U.S. and Europe accounted for approximately 75% of patients enrolled, with the U.S.-based sites representing the highest enrolling country.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- SLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Sellas Life Sciences price target raised to $7 from $4 at Maxim
- Sellas Life Sciences meets all primary endpoints in Phase 2 trial of SLS009
- Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board
- Largest borrow rate increases among liquid names